Compare APAM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | BEAM |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2013 | 2020 |
| Metric | APAM | BEAM |
|---|---|---|
| Price | $44.37 | $30.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $46.00 | ★ $46.42 |
| AVG Volume (30 Days) | 397.5K | ★ 1.8M |
| Earning Date | 02-03-2026 | 02-24-2026 |
| Dividend Yield | ★ 8.19% | N/A |
| EPS Growth | ★ 2.95 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $1,158,234,000.00 | $55,701,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $7.04 | $26.52 |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $32.75 | $13.53 |
| 52 Week High | $48.50 | $36.44 |
| Indicator | APAM | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 57.61 |
| Support Level | $42.27 | $27.29 |
| Resistance Level | $44.77 | $36.18 |
| Average True Range (ATR) | 1.02 | 2.27 |
| MACD | 0.25 | 0.38 |
| Stochastic Oscillator | 89.46 | 48.77 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. In addition to its equity strategies, customers may invest in a fixed-income strategy. Strategies are often distributed to customers ranging from retail investors to institutional investors through specialized channels.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.